The revitalization of the Institute of Immunology is a strategic project of the Republic of Croatia that involves the construction of new manufacturing facilities at the location of the Rugvica industrial zone (north), Rugvica Municipality and the restarting of the production of biological medicinal products in the Republic of Croatia.
Photo: The visualization shown includes the COMPLEX OF NEW PLANTS FOR THE PRODUCTION OF VIRAL VACCINES (PHASE II)
Photo: The visualization shown includes the NEW ADMINISTRATIVE BUILDING OF THE INSTITUTE OF IMMUNOLOGY
The Croatian pharmaceutical industry is recognized as a driving force and one of the strategic industrial activities in the Republic of Croatia. The Institute of Immunology is a legal entity of public health and strategic state interest as a manufacturer of vaccines, antisera and medicinal products derived from human blood or human plasma in the Republic of Croatia with a 130-year tradition, whose production is undergoing revitalization processes, with the particular importance of the master seeds of measles, rubella, and mumps viruses produced by the Institute of Immunology, which are now owned by the Republic of Croatia. The revitalization of the Institute of Immunology is strategically important for the Croatian health and economic system because it creates:
a foundation for the biotechnological independence of the Republic of Croatia
a foundation for a more efficient reform and sustainability of the health system of the Republic of Croatia
added value in the context of economic growth and development of the Republic of Croatia
The construction of new manufacturing facilities brings several key benefits. The capacities of these facilities financially justify the construction, thus ensuring the sustainability of the project. With the new facilities, the Republic of Croatia will be able to ensure a sufficient quantity of strategically important products at all times, thus reducing dependence on imports and increasing security.
Preserving its domestic production will stimulate the development of biotechnology in the country in the long term and open up opportunities for the employment of highly qualified young people, who will have the opportunity to work in their own environment. The revitalization also enables further development and employment of subcontractors of the Institute of Immunology, thus strengthening cooperation within the biotechnology industry.
With the new facilities, Croatia will have the opportunity to develop new vaccines in its own research center, which will increase its capacity for research and innovation. It also opens up the possibility of strategic cooperation in the production of new vaccines, thus positioning the country as an important player in the global biotechnology industry.
Availability of quality viral vaccines necessary for the prevention of various infectious diseases.
Supply of plasma derived medicinal products in sufficient quantities exclusively from plasma collected in the Republic of Croatia.
Providing European Viper Venom Antiserum (Equine) which guarantees safety and protection from the snake – bite envenoming of bites by European snakes from the viper family.
Ensuring employment of national human resources.
Significant export effect through planned product placement.
Domestic production ensures rationalization of the procurement of biological medicinal products for the Republic of Croatia in relation to product imports.